Nxera Pharma Co., Ltd. (SOLTF)
| Previous Close | 0.00 |
| Open | 7.00 |
| Bid | 7.61 x 40000 |
| Ask | 8.59 x 40000 |
| Day's Range | 7.00 - 7.00 |
| 52 Week Range | 7.00 - 13.43 |
| Volume | |
| Avg. Volume | 64 |
| Market Cap | 721.573M |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.77 |
| Earnings Date | Nov 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 27, 2015 |
| 1y Target Est | N/A |
GlobeNewswireNxera Pharma to Host R&D Day 2024
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date: Wednesday, 6 November 2024 Time: 16:30 – 18:00 JST (7:30 – 9:00 GMT) Presenters: Chris Cargill, President and CEO Dr. Matt Barnes, Executive Officer, President of Nxera Pharma UK and Head of R&DDr. Makoto Sugita, Executive Officer, Chief Medical Officer (CMO) and President of Nxera Pharma JapanHironoshin Nomura, E
- GlobeNewswire
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Exec
